NasdaqGM:STIMMedical Equipment
Neuronetics (STIM): Ongoing Losses Challenge Bullish Narratives Despite Forecast 12.1% Revenue Growth
Neuronetics (STIM) is currently unprofitable, with annual losses widening by 10.3% on average over the past five years. Despite no improvement in net profit margin and the expectation that the company will remain unprofitable for at least the next three years, revenue is forecast to climb 12.1% a year, outpacing the broader US market’s 10.5% growth rate. Investors are likely to weigh the company’s above-average growth prospects and relatively attractive price-to-sales ratio of 1.5x against...